Avanos Medical Acquired by American Industrial Partners in $1.27B Deal
Event summary
- Avanos Medical has agreed to be acquired by affiliates of American Industrial Partners (AIP) for approximately $1.272 billion.
- Avanos stockholders will receive $25.00 per share in cash, representing a 72.1% premium to the closing stock price and an 82.8% premium to the 30-day average.
- The acquisition, unanimously approved by Avanos' Board, is expected to close in the second half of 2026, subject to regulatory approvals.
- Upon completion, Avanos will become a private company and delist from the New York Stock Exchange.
The big picture
The acquisition of Avanos Medical by American Industrial Partners, a firm with $17.5 billion in AUM, signals a continued appetite for medical technology assets among private equity firms. AIP’s operational expertise suggests a focus on streamlining Avanos’ operations and potentially pursuing add-on acquisitions to accelerate growth. This deal highlights a trend of public companies being taken private to unlock value through focused management and strategic initiatives.
What we're watching
- Integration Risk
- AIP’s operational focus will be tested by integrating Avanos’ existing business units and brands, potentially leading to disruption if not managed effectively.
- Regulatory Scrutiny
- Given the size of the deal, the Hart-Scott-Rodino Act review will be critical; any significant delays or conditions could impact the transaction's timeline and value.
- Debt Load
- While the press release states there is no financing condition, the acquisition will likely increase Avanos’ debt load under AIP’s ownership, potentially impacting future investment flexibility.
Related topics